Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance
$0.00
Program DescriptionThe understanding and prognosis of patients with myasthenia gravis (MG) have made dramatic leaps since the advent of serological evaluation and immunotherapy. In fact, clinicians have become so confident in the ability to diagnose and manage MG that prominent medical organizations commonly boast the ability of these patients to lead “normal lives.” However, studies find that clinician and patient perceptions are often not the same.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Attendance
$0.00
OverviewThough neuromyelitis optica spectrum disorder (NMOSD) has had a specific lab marker (AQP4 antibody) for many years, its relapsing nature and overlapping syndromes still cause it to be confused with multiple conditions such as multiple sclerosis (MS), leading to inappropriate and even harmful treatment. The emergence of similarly presenting MOG antibody disease (MOGAD) as its own entity has further complicated the picture.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance
$0.00
Program DescriptionRecent advances in the understanding of the genetics of epilepsy have led to new insights that stand to significantly improve treatment for individual patient presentations and needs. With several anti-seizure medications (ASMs) now approved (e.g., cannabidiol, fenfluramine, ganaxolone) for syndromes with expanding indications, genetic testing may impact treatment decisions for a large population of patients.
$0.00
OverviewAdvancements in the understanding of the pathophysiological mechanisms underlying multiple sclerosis (MS) have surged in recent years including increasing recognition that brain damage and subsequent disease worsening may occur earlier and more subtly than previously recognized. To date, there is no consensus regarding the relative roles of individual indicators of prognosis and/or disease worsening (e.g., brain atrophy, conventional MRI, cognitive impairment) in clinical decision-making.
$0.00
OverviewAcute ischemic stroke (AIS) is one of the leading causes of death and disability in the US. As a provider’s quick thinking and rapid actions are critical to patient outcomes, it is essential that clinicians are proficient and coordinated in optimized approaches to its management. But despite this need for cohesion, several elements of stroke work-up and treatment lack clear consensus and strategies are easily disrupted by challenges with clinic flow and variations in access/expertise.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance
$0.00
OverviewUp to 80% of patients with bipolar disorder (BD) initially present with depression. However, without experience of or insight into their mania, these patients are easily misdiagnosed with major depressive disorder (MDD) or other psychiatric conditions. Once an accurate diagnosis is obtained, ensuring appropriate treatment of BD depression is essential, but a variety of misconceptions and outdated strategies significantly complicate this process.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance
$0.00
Program DescriptionWith recent approvals of amyloid-targeting therapies (ATTs) for patients with mild cognitive impairment (MCI) and early Alzheimer’s disease (AD) neurobiology, AD management is facing an imminent paradigm shift.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance
$0.00
Program DescriptionSleep experts Drs. Lynn Marie Trotti, Asim Roy, and Anne Marie Morse offer a comprehensive approach to narcolepsy treatment, embracing recent pharmacological advancements (e.g., pitolisant, solriamfetol, low sodium oxybate [LXB], once nightly sodium oxybate [ON-SXB]). Learners will explore how to tailor individual treatment regimens by moving beyond traditional focuses like cataplexy and excessive daytime sleepiness to address newer concerns such as disrupted nighttime sleep and autonomic dysfunction.
$0.00
Program DescriptionThe care of Alzheimer’s disease (AD) is involved, multifaceted, and variable depending on individual patient preferences. With the introduction of novel tools and strategies for diagnosis and therapy, additional clinicians and responsibilities are being introduced into AD management each day. Though these developments are highly promising for patients, their integration is complicated by the wide breadth of providers in disparate practice locations/specialties that can be responsible for them.
$0.00
Alzheimer’s disease (AD) is a complex condition to diagnose and treat due to its significant overlap in symptoms and even pathological elements with other conditions. Notably, only half of AD cases are diagnosed and, when they are, diagnosis typically occurs several years following symptom onset. These issues only worsen for patients evaluated during earlier stages of AD. Now that disease-modifying therapies (DMT) specifically targeting early AD pathology are beginning to enter the therapeutic armamentarium, early diagnosis is becoming more critical than ever.